The global fight against antibiotic resistance is facing significant challenges, with a diminishing number of scientists working on new antibiotics. Despite the urgent need for novel antibiotics, financial disincentives and high costs of clinical trials are major barriers. Only 17 new systemic antibiotics and one related biologic received FDA approval between 2010 and May 2021. In 2024, only three antibiotics, including Zevtera, have been approved for human use. The AMR Action Fund is one of the few private investment firms backing antibiotic development. Basilea received up to $134 million from BARDA to fund its Phase 3 trials. Japanese pharmaceutical company Shionogi is expanding its antimicrobial research operations and establishing a discovery lab in San Diego. Experts warn that without new antibiotics, the world risks a public health crisis and jeopardizing global health security. Financial disincentives, such as the risk of bankruptcy, deter companies from developing new antibiotics. In the 1990s, plenty of pharmaceutical companies had scientists working on novel antibiotics. The National Institutes have noted that physicians often prefer cheaper, generic antibiotics even when they are less effective.
"In the race between antibiotic drug development and increasing resistance, the pathogens are winning..If new antibiotics are not discovered and developed, we cannot overcome this public health crisis and are at risk of jeopardizing global health security” https://t.co/ZFasoqqONv
Antimicrobial resistance is one of the biggest health challenges the world faces. To take on this global problem, we need a more coordinated, worldwide response ⤵️ https://t.co/DlxJ3v9TaY
In antibiotics investment news, Japanese pharma Shionogi announced at #bio2024 conf that they're expanding their global infectious disease & antimicrobial research ops & establishing their 1st discovery lab in US in San Diego w/ their @Qpexbio subsidiary https://t.co/O3uwgesIfz https://t.co/7Jm5IQeodb
Basilea wouldn’t have been able to fund another Phase 3 trial w/out the help of a partner they told @rowanwalrath. Basilea execs estimated that US govt's BARDA covered ∼70% of the project’s costs & company received up to $134M grant that began in '16. https://t.co/YvW55I9QGz
Large-scale clinical trials can cost companies hundreds of millions of $ & take yrs to finish. Basilea wouldn’t have been able to fund another Phase 3 w/out the help of a partner. Basilea execs estimate BARDA covered ∼70% of the project’s costs & company received up to $134M… https://t.co/YvW55I9iR1
The AMR Action Fund is only 1 of just a small # of private investment firms currently that back companies developing novel antibiotics. In the 1990s, Roche had an anti-infectives unit & "plenty of pharmaceutical companies had scientists working on novel antibiotics, inspired… https://t.co/vHSghAkVYx
The AMR Action Fund is only 1 of just a handful of private investment firms currently that back companies developing novel antibiotics. In the 1990s, Roche had an anti-infectives unit & "plenty of pharmaceutical companies had scientists working on novel antibiotics, inspired… https://t.co/vHSghAkVYx
"There’s a unique web of disincentives for new antibiotic development....physicians tend to prefer generic antibiotics that have been on the market for decades—even when those drugs aren’t working—because they’re cheaper & broadly known to be safe. A recent National Institutes… https://t.co/DGMiOJGFMk
Only 17 new "systemic antibiotics" & 1 related biologic received FDA approval betw '10 & 5/21 said story below. "Experts worry that even that number could represent a peak. These approvals were decades in the making & a labyrinth of scientific, financial, & regulatory challenges… https://t.co/YvW55I9iR1
What happens when the reward for making a new antibiotic is bankruptcy?—asks @cenmag story by @rowanwalrath. Zevtera is 1 of 3 antibiotics to gain FDA approval for humans so far in '24. Outside of '24, US has approved few new antibiotics in recent yrs https://t.co/JvaY4sQ7uE https://t.co/oDhd3YcdMs
To fight an existential-scale threat like antibiotic resistance, the world needs all the brainpower it can muster. Just the opposite is happening, with an ever-diminishing number of scientists working to… https://t.co/MAZDysuSZd